65,437 trials
Prostate Cancer
Primary: Percentage of Participants Successfully Completed 99mTc-sulfur Nanocolloid SPECT/CT Within 3 Hours After Injection — 100 Percentage of Participants
Diabetes Mellitus · Peripheral Neuropathy · Plantar Ulcers
Primary: Plantar Flexor Muscle Strength — -8; 3; 6 Plantar Flexor Torque (Nm)
Hepatitis C, Chronic
Primary: Sustained Virologic Response (SVR) Rate in Full Analysis Set (FAS) Population. — 20.9; 64.2 Percentage of Participants
Cataract
Primary: Decision to Undergo Cataract Surgery (Surgery Acceptance) — 31.1; 34.2 percentage of participants
Arthritis, Rheumatoid
Primary: Number of Participants Who Had the Mendel Mantoux Test as the First Screening Test for Active or Latent Tuberculosis (TB) Before Starting Treatment — 481; 26; 1…
Short Bowel Syndrome
Primary: Responder — 27; 13 subjects — p=0.002
Spondylitis, Ankylosing
Primary: Number of Participants Who Had the Mendel Mantoux Test as the First Screening Test for Active or Latent Tuberculosis (TB) Before Starting Treatment — 310; 9; 1…
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 26 — -1.15; -0.40 Percent of glycosylated hemoglobin
Intra-Abdominal Infections · Skin Disease, Infectious · Soft Tissues Infections
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 11; 45; 4; 28 participants
Kidney Cancer
Primary: Tumor Burden Reduction Rate (TBRR) — 30; 70 percentage of patients
Colonoscopy
Primary: Discharge Time, the Time to Reach a Modified Aldrete Score ≥18 — 0; 0; 2 minutes
Kidney Disease, Chronic
Primary: Key Outcome as Per Statistical Analysis Plan = Major Atherosclerotic Events Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients…
Essential Tremor
Primary: Normalized Mean Tremor Amplitude for Both Formulations of 64 mg/kg 1-Octanol in Part B — 1; 1; 1.009; 0.901 normalized score on a scale
Atrial Fibrillation
Primary: Dose-response Relationship for QTcF Interval of AZD1305 — 461; 486; 490; 482 ms
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline at Week 12 — -0.15; -0.76 Percent — p=< 0.0001